Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH episode artwork

EPISODE · Dec 8, 2025 · 15 MIN

Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH

from BiotechTV - News · host BiotechTV

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.

NOW PLAYING

Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH

0:00 15:36

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 15 minutes long.

When was this BiotechTV - News episode published?

This episode was published on December 8, 2025.

What is this episode about?

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new...

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!